These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25752488)

  • 1. Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).
    Pechalrieu D; Lopez M
    Expert Opin Ther Pat; 2015 Jun; 25(6):729-35. PubMed ID: 25752488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator.
    Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR
    Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation, identification and drug sensitivity pattern of mycobacterial strains isolated from human patients.
    Nain PS; Chandiramani NK; Darg DN
    Indian J Pathol Microbiol; 1987 Jul; 30(3):261-6. PubMed ID: 3130312
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Sawicki R; Ginalska G
    Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and docking studies of potent ethionamide boosters.
    Tatum NJ; Villemagne B; Willand N; Deprez B; Liebeschuetz JW; Baulard AR; Pohl E
    Acta Crystallogr C; 2013 Nov; 69(Pt 11):1243-50. PubMed ID: 24192167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016).
    da Silva PB; Campos DL; Ribeiro CM; da Silva IC; Pavan FR
    Expert Opin Ther Pat; 2017 Mar; 27(3):269-282. PubMed ID: 27796146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mycobacterial species repartition: experience of the Antituberculosis Center in Pointe Noire (Republic of Congo)].
    Ontsira Ngoyi EN; Obengui ; Taty Taty R; Koumba EL; Ngala P; Ossibi Ibara RB
    Bull Soc Pathol Exot; 2014 Dec; 107(5):342-5. PubMed ID: 25260392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-resistance in Mycobacterium tuberculosis in Castilla y León, Spain, 2001-2005: third collaborative study].
    Alberte-Castiñeiras A; Campos-Bueno A; López-Urrutia L; Alvarez-Alonso E; Megías G; Ojeda-Fernández E; López-Medrano R; Iglesias-García J; García-Carbajosa S; Pérez-Pascual P
    Enferm Infecc Microbiol Clin; 2010 Dec; 28(10):706-9. PubMed ID: 20627375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis drug resistance: summary report for 2003.
    Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycobacterial efflux pumps and chemotherapeutic implications.
    Viveiros M; Leandro C; Amaral L
    Int J Antimicrob Agents; 2003 Sep; 22(3):274-8. PubMed ID: 13678834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of the antituberculosis drug ethionamide.
    Vale N; Gomes P; Santos HA
    Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS].
    Pulido F; Iribarren JA; Kindelan JM; Moreno S
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():20-8. PubMed ID: 9859616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of drug resistant tuberculosis].
    Perel'man MI; Sokolova GB; Borisov SE; Kunichan AD; Lazareva IaV; Mozhokina GN; Elistratova NA; Tsybanev AA
    Antibiot Khimioter; 2003; 48(8):28-36. PubMed ID: 14722939
    [No Abstract]   [Full Text] [Related]  

  • 16. Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors.
    Grant SS; Wellington S; Kawate T; Desjardins CA; Silvis MR; Wivagg C; Thompson M; Gordon K; Kazyanskaya E; Nietupski R; Haseley N; Iwase N; Earl AM; Fitzgerald M; Hung DT
    Cell Chem Biol; 2016 Jun; 23(6):666-77. PubMed ID: 27321573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.
    Grau T; Selchow P; Tigges M; Burri R; Gitzinger M; Böttger EC; Fussenegger M; Sander P
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1142-5. PubMed ID: 22106218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-Based Optimized EthR Inhibitors with
    Villemagne B; Machelart A; Tran NC; Flipo M; Moune M; Leroux F; Piveteau C; Wohlkönig A; Wintjens R; Li X; Gref R; Brodin P; Deprez B; Baulard AR; Willand N
    ACS Infect Dis; 2020 Mar; 6(3):366-378. PubMed ID: 32011115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New active leads for tuberculosis booster drugs by structure-based drug discovery.
    Tatum NJ; Liebeschuetz JW; Cole JC; Frita R; Herledan A; Baulard AR; Willand N; Pohl E
    Org Biomol Chem; 2017 Dec; 15(48):10245-10255. PubMed ID: 29182187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation-drug resistance profile and molecular characterization of indigenous typical and atypical mycobacteria.
    Khanum T; Rasool SA; Ajaz M; Khan AI
    Pak J Pharm Sci; 2011 Oct; 24(4):527-32. PubMed ID: 21959816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.